PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29669582-3	2018	This study aimed to examine the efficacy of galantamine, a clinically approved cholinergic agent, in alleviating LPS-induced neuroinflammation and cognitive decline as well as the associated mechanism.	Galantamine	44-55	toll-like receptor 4	Mus musculus	113-116	
29669582-10	2018	Galantamine decreased the expression of microglia and astrocyte markers (CD11b and GFAP), pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha), and NF-kappaB p65 in the hippocampus of LPS-exposed mice.	Galantamine	0-11	toll-like receptor 4	Mus musculus	190-193	
29669582-11	2018	Furthermore, galantamine ameliorated LPS-induced loss of synapse-associated proteins (SYN and PSD-95) in the hippocampus.	Galantamine	13-24	toll-like receptor 4	Mus musculus	37-40